Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

Eichenauer, Dennis A.; Pluetschow, Annette; Kreissl, Stefanie; Soekler, Martin; Hellmuth, Johannes C.; Meissner, Julia; Mathas, Stephan; Topp, Max S.; Behringer, Karolin; Klapper, Wolfram; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Fuchs, Michael; Diehl, Volker; Engert, Andreas; Borchmann, Peter

dc.contributor.author	Sökler, Martin
dc.date.accessioned	2019-04-02T07:49:02Z
dc.date.available	2019-04-02T07:49:02Z
dc.date.issued	2017
dc.identifier.issn	1474-5488
dc.identifier.uri	http://hdl.handle.net/10900/87397
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(17)30696-4	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190131163842_00248
utue.publikation.seiten	1680-1687	de_DE
utue.personen.roh	Eichenauer, Dennis A.
utue.personen.roh	Pluetschow, Annette
utue.personen.roh	Kreissl, Stefanie
utue.personen.roh	Soekler, Martin
utue.personen.roh	Hellmuth, Johannes C.
utue.personen.roh	Meissner, Julia
utue.personen.roh	Mathas, Stephan
utue.personen.roh	Topp, Max S.
utue.personen.roh	Behringer, Karolin
utue.personen.roh	Klapper, Wolfram
utue.personen.roh	Kuhnert, Georg
utue.personen.roh	Dietlein, Markus
utue.personen.roh	Kobe, Carsten
utue.personen.roh	Fuchs, Michael
utue.personen.roh	Diehl, Volker
utue.personen.roh	Engert, Andreas
utue.personen.roh	Borchmann, Peter
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	12	de_DE
dcterms.isPartOf.ZS-Volume	18	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE